This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 202| Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
|---|---|---|---|---|---|---|---|---|---|
| 2451 | IPO9 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.64 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2452 | MTA3 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.61 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2453 | CSRP2BP | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.57 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2454 | XPO1 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.44 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2455 | C14orf93 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.43 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2456 | C5orf13 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.56 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2457 | EHMT2 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.80 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2458 | STX6 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.24 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2459 | MCM8 | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 2.34 ) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2460 | MEF2B | RNAs | Human | Upregulated in highly invasive HCC than less-invasive HCC (with fold change of 1.49) | Prognostic | less (L) invasive HCC v/s highly (H) invasive HCC; associated with survival of patients | p < 0.01 | Tissue | 19945130 |
| 2463 | CLU | RNAs | Human | Upregulated in metastatic HCC than primary HCC | Diagnostic and Prognostic | Primary and metastatic HCC | p < 0.001 | Cell line and Tissue | 16247463 |
| 2466 | MT1B, MT1E, MT1L, CP, ABCA1, CACNB3, PROS1, CPB2, SERPINC1, LACI, MDK, C6, C9, CD5L, GPR126, IL1RAP, DYRK3, PCDH17, TACSTD1, UAP1, C20orf3, CFL2, FLJ12666, KIAA0843, MRC1, NAT2, MYO1B, SIPL, SRD5A2, USP1, | RNAs | Human | Differentially expressed (PCDH17, MDK, TACSTD1 Upregulated and rest 27 are Downregulated) in High-risk individuals with cirrhosis v/s patients with HCC | Prognostic | High-risk individuals with cirrhosis v/s patients with HCC | p < 0.0003 | Tissue | 14768006 |
| 2472 | AURKB | Protein and RNAs | Human | Upregulated in HCC tissues in association with aggressive recurrence v/s non-recurrence | Prognostic | Aggressive recurrence HCC v/s non-recurrence HCC | p < 0.001 | Tissue | 18311747 |
| 2499 | SEMA3F, DDX17, TNFAIP, PDGFRA, VIM, LAPTM5, CCND2, HLADRA, MEF2C, Staf50, SGK, REL, | RNAs | Human | Diffrenetially Expressed between recurrent and non-recurrent HCC | Prognostic | Early intrahepatic recurrence and non-recurrence HCC | p < 0.05 | Tissue | 12648972 |
| 2520 | Gain of Chromosome 7 | Copy Number variation | Human | Chromosome 7 median copy number > 2.2 associated with early recurrence (within 2 years) in HCC (with Hazard ratio 5.8) | Prognostic | Early recurrence v/s late recurrence | p < 0.001 | Tissue | 18701503 |
| 2521 | Gain of Chromosome 7 | Copy Number variation | Human | Chromosome 7 median copy number > 2.2 associated with overall recurrence in HCC (with Hazard ratio 3.4) | Prognostic | Early recurrence v/s late recurrence | p < 0.001 | Tissue | 18701503 |
| 2524 | HIF1A | RNAs | Human | Upregulated in 17 HCC patients ( with fold change 2.14, ±0.93) and downregulated in 36 HCC patients (with fold change 0.75, ±0.26) in the HCC compared to corresponding non-malignant liver tissue | Prognostic | HCC v/s non-tumor; predict recurrence of HCC in patients | p < 0.001 | Tissue | 20165955 |
| 2531 | TRIM25, EIF2S3, CLECSF14, DXYS155E, T-cell receptor beta locus, GIF2H2, SPON2, VDAC2, SLC15A3, HBP1, PTPRC, FES, CDC5L, ITGB2, MPP1, NDUFA2, AHCYL1, CNP, SQLE, RPA3, LGALS1, HLA-DQA1 , STMN1, PCOLCE, LOC387680, DPT, SLK, IGBP1, SNRPG, Human-alpha1-antitrypsin gene (S variant) complete cds, SIAHBP1, | RNAs | Human | 7 genes Downregulated i.e. CYP1A2, Human-alpha1-antitrypsin gene (S variant) complete cds, PCOLCE, CNP, DXYS155E, CLECSF14, TRIM25 and 29 get upregulated in | Diagnostic and prognostic | Single nodular HCC group v/s multicentric HCC group; associated with multicentric recurrence | p < 0.05 | Tissue | 16788756 |
| 2535 | ADAR, PSMD4, D9SVA, CCT3, GBAP, RDBP, CSRP2, ILR7 | RNAs | Human | ILR-7 is Downregulated while others are Upregulated in | Prognostic | Moderately differentiated tumor (MD) v/s Well-differentiated tumor (WD) | p < 0.05 | Tissue | 12079511 |
| 2536 | AF147376, FLJ20084, LRP8, DKK2, AK027155, AK002039, PLSCR4, AK021998, ESDN, AKR7A2, MAP2K2, AL133075, APOL3, AK023559, GNRHR, COQ6, AF086143, FLJ14117, HUMCYT2A, D25272, M37712, KLK12, ZNF205, NM_001758, AK001102, KIAA0562, CIAO1, SRRM2, UBE1, FBXO10, AF113699, APOB, D86974, Z70704, SFRS2IP, WDFY1, | RNAs | Human | Discriminating among early-stage samples (between LGDN, HGDN and G1) | Prognostic | Dysplastic nodules of HCC v/s Edmondson grade 1 | p < 0.001 | Tissue | 16175600 |
| 2537 | SLC38A2, AF116620, MYO1B, SULT2A1, PRRG1, FLJ14153, C8A, HSPB7, UBE2D3, AF143323, CTH, L08441, DSIPI, NYD-SP21, AFG3L1, HGD, LRP8, SDHD, ALPL, HPX, AK022053, AK027242, RFX5, GALNT10, KIAA1671, NFKBIB, LOC149832, UACA, GNG10, AL110138, AK026168, INHBA, LAMP1, MLL5, MLLT6, Z36876, BDG29, FLJ12800, ARN | RNAs | Human | Discriminating among late-stage sample (between G1, G2 and G3) | Prognostic | Edmondson grade 1 HCC v/s Edmondson grade 2/3 HCC | p < 0.001 | Tissue | 16175600 |
| 2539 | NRCAM, CD24, CTHRC1, ROBO1, CENPM, FOXQ1, CDCA7L, MYBL2, PAFAH1B3, STK39, SPINK1, AKR1B10, SLC6A8, SOX4, | RNAs | Human | Upregulated in T3 than T1 and adjacent non-tumor (with 6 fold change) | Prognostic | Intrahepatic metastasis v/s primary HCC and normal | p < 0.05 | Tissue | 18504433 |
| 2540 | SOX4 | RNAs | Human | Upregulated in T3 than T1 and adjacent non-tumor (with 6 fold change) | Prognostic | Intrahepatic metastasis v/s primary HCC and normal | p < 0.05 | Tissue | 18504433 |
| 2541 | UCP2, MSR1, HPSE, CCL2, FCER1G | RNAs | Human | Downregulated in HCV-HCC carcinogenesis progression | Prognostic | HCV-HCC v/s early HCV cirrhosis, late HCV cirrhosis, and normal liver tissues | p < 0.05 | Tissue | 15108252 |
| 2542 | S100P, CD24, GPC3, DLK1, TM4SF3 | RNAs | Human | Upregulated in HCV-HCC carcinogenesis progression | Prognostic | HCV-HCC v/s early HCV cirrhosis, late HCV cirrhosis, and normal liver tissues. | p < 0.05 | Tissue | 15108252 |
| 2543 | TACSTD1, MYH4, PSPHL, CXCR4, N33, GMNN, MGP, RGS2, G1P2, AREG, EMP1, IFIT1, SPINK1, ADAMTS1, SLC2A3, EPHA3, GJA1, RDC1, KCNJ16, MX1, KRT23, THBD, MTHFD2, IFI44, IGF1, SGCE, SPARCL1, CYP3A5, ATP8B1 | RNAs | Human | Downregulated in late cirrhosis than early cirrhosis (with more than 3 fold) | Prognostic | Early v/s Late HCV Cirrhosis | p < 0.05 | Tissue | 15108252 |
| 2544 | SQLE, KIAA1919, ALDH4A1, NKTR, DICER1, C1QB, CYP2A6, EIF1AY, LPA, AKR1C4, GNMT, HLA-DRB4, IGFBP2, GPR88, MBD4, DEFA1, MADH1, HFR4, KIAA1847, FTHFD, SAA1, ASS, CRP, APOF, DBY, ATF5, RPS4Y, SAA2 | RNAs | Human | Upregulated in late cirrhosis than early cirrhosis (with more than 3 fold) | Prognostic | Early v/s Late HCV Cirrhosis | p < 0.05 | Tissue | 15108252 |
| 2545 | CDC42EP 4, IVNS1AB P, QTRT1, A2BP1, EDF1, ANXA2P3, ZNF706, STAT6, CDKN1C, DUSP6, PLOD1, ATP2A3, FAM65A, SIPA1, NCK2 | RNAs | Human | Downregulated in HCV-Cirrhosis with HCC than HCV-cirrhosis only (with fold change more than 1.3) | Prognostic | HCV-Cirrhosis v/s HCV-Cirrhosis with HCC | p < 0.05 | Tissue | 19098997 |
| 2546 | HLA-DR | Protein and RNAs | Human | Downregulated in HCC with early IHR vs. HCC without recurrence (with Fiser ratio 1.56) | Prognostic | Intrahepatic recurrence v/s Non-recurrence | p < 0.05 | Tissue | 15688398 |
| 2547 | FBN1, MEF2C, TNFAIP3, LAPTM5, TMSB4X, CUGBP2, HLA-DRA, REL, clone110298, LTBP2, TRIM22, HLA-DRBI, FOXF1, HLA-DQA, SDF1, DDX17, SGK, PDGFRA, F2R, HLADG, MTAP44, CTSK, VIM, ACVR1, ON/SPARC, SCYA3, ARHGEF6, CCND2, COL1A1, ITGB2/CD18, PTPRC, MKNK1, JUNB, EST, GATA6, FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP | RNAs | Human | 11 genes (FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP, FUT1, GCHFR, CYP2A, MLH1, EST) Upregulated and rest 35 genes downregulated in HCC with early IHR vs. HCC without recurrence | Prognostic | Intrahepatic recurrence v/s Non-recurrence | p < 0.05 | Tissue | 15688398 |
| 2556 | VAMP2, ALDH3A2, DPP4, CCL3, HAPLN1, MAN2B1, RBPMS, ACSL6, ITPR2, PLEKHM2, RNF115, CIC, CALR, CENPN | RNAs | Human | Differentially expressed gene | Prognostic | cirrhotic liver tissues with and without hepatocellular carcinoma; can predict prognosis of HCC | p < 0.01 | Tissue | 19861515 |
| 2557 | DPP4, CALR | RNAs | Human | Differentially expressed gene | Prognostic | cirrhotic liver tissues with and without hepatocellular carcinoma; can predict prognosis of HCC | p < 0.01 | Tissue | 19861515 |
| 2558 | DPP4, VAMP2, EGR1 | RNAs | Human | Differentially expressed gene | Prognostic | cirrhotic liver tissues with and without hepatocellular carcinoma; can predict prognosis of HCC | p < 0.01 | Tissue | 19861515 |
| 2559 | IL1A,IL1B,IL2,IL12A,IL12B,IL15,IFNG,TNF,IL4,IL5,IL8,IL10,CSF1,ANXA1,HLA-DRA,HLA-DPA1,PRG1 | RNAs | Human | Diffrentially expressed between MIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment ) | Prognostic | MIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment ) | p < 0.05 | Tissue | 16904609 |
| 2560 | IL1A,IL1B,IL2,IL12A,IL12B,IL15,IFNG,TNF,IL4,IL5,IL8,IL10,CSF1,ANXA1,HLA-DRA,HLA-DPA1,PRG1 | RNAs | Human | Diffrentially expressed between MIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment ) | Prognostic | Recurrence v/s non-recurrence | p < 0.05 | Tissue | 16904609 |
| 2561 | HSP70 | Protein | Human | Upregulated in early HCC components | Diagnostic and prognostic | nodule-in-nodule-type HCCs and corresponding noncancerous liver tissues | p< .001 | Tissue | 12500205 |
| 2564 | EFNA1 | Protein and RNAs | Human | Upregulated in HCC | Diagnostic and Prognostic | HCC v/s non-tumor/normal; associated with the poor survival of patients | p< 0.001 | Tissue and Seum | 19642143 |
| 2565 | EphA2 | Protein and RNAs | Human | Downregulated in HCC | Diagnostic and Prognostic | HCC v/s non-tumor/normal; associated with the poor survival of patients | p < 0.05 | Tissue and Seum | 19642143 |
| 2568 | VIM or Vimentin | RNAs | Human | Upegulated in HCC | Prognostic | Primary v/s metastasis; significantly associated with HCC metastasis | p< 0.01 | Tissue | 14647434 |
| 2580 | Dystrophin, Homolog to tubulin beta chain, Zinc finger protein 337, Friedreich ataxia region gene X123, Fibronectin (Alt. Splice 1), Zinc finger protein 9, Metallothionein IV, Poly(rC) binding protein 3, KIAA0426 gene product, Hypothetical protein FLJ13910, RAN binding protein 2 like 1, S100 calcium | RNAs | Human | Downregulated in L1 than L0 (with fisher ratio more than 9.74) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s and L0 (without HCV infection) ; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2581 | Cystatin C, Prolylcarboxypeptidase (angiotensinase C), Lysyl-tRNA synthetase, Voltage-dependent anion channel 3, Protective protein for beta-galactosidase (cathepsin A), Interferon gamma-inducible protein 30, Signal sequence receptor delta, Thioredoxin-related transmembrane protein, Cathepsin D, Ras | RNAs | Human | Upregulated in L1 than L0 (with Fisher ratio more than 8.9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s and L0 (without HCV infection) ; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2582 | Mannose receptor C type 1, BCL2/adenovirus E1B 19 kD interacting protein 3 like, v-fos FBJ murine osteosarcoma viral oncogene homolog, Ficolin 3 (Hakata antigen), Calmodulin 1, v-maf musculoaponeurotic fibrosarcoma oncogene homolog, Metallothionein 1H, Metallothionein 1E, Solute carrier family 31 me | RNAs | Human | Downregulated in G1 than L1 (with fisher ratio more than 9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s G1 (well differentiated) HCV-HCC; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2583 | SNRPB, TBCE, DRAP1, UFD1L, MT4, ATP6V1E, calmodulin dependent protein kinase 2, ZFP103, ATOX1, Interleukin enhancer binding factor 2 | RNAs | Human | Upregulated in G1 than L1 (with fisher ratio more than 9) | Prognostic | non-tumorous livers L1 (with HCV infection) v/s G1 (well differentiated) HCV-HCC; associated with invasion or metastsis | P = 0.001 | Tissue | 15710396 |
| 2584 | OAS2, ADH1A, FLJ20378, HSF2, PSME1, E2L6, UBE2L6, STAT1, LIM, FLN29, GABARAPL1, | RNAs | Human | Downregulated in G2 than G1 (with fisher ratio more than 1.7) | Prognostic | G1 (well differentiated) HCV-HCC v/s G2 (moderately differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2585 | RPNI, ZNF161, EIF4G1, FNBP3, CCT6A, PPIB, IMPA2, GORASP2, KIAA0669, ATP2A2, PA200, ZNF91, GOLGA4, KIAA0494, SIAH1, UBQLN2, ADNP, TPD52L2, FDPS, DICER1 | RNAs | Human | Upregulated in G2 than G1 (with fisher ratio more than 1.7) | Prognostic | G1 (well differentiated) HCV-HCC v/s G2 (moderately differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2586 | APOC1, SEPP1, PDZGEF1, SCML2, ALDH5A1, BNIP3, FBXW1B, PAH, Homo sapiens clone 24473 mRNA sequence, PACE4, FLJ31305 fis or clone LIVER1000104 or , Unknown or , MIG2, RARRES2, BAAT, KDELR2, RNP24, FACL2, KIAA0977 protein, HADHSC, HADHSC, SDHD, CPB2, PGRMC1, AOP2, PPM1A, SDC1, CCL14, EST | RNAs | Human | Downregulated in G3 compared with G2 (with Fisher ratio more than 1.3) | Prognostic | G2 (moderately differentiated) HCV-HCC v/s G2 (poorly differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2587 | DAZAP2, SPINT1, LGALS9, CYBA, BAZ2A, PPT1, S100A13, LGALS9, PIM2, TGFB1 | RNAs | Human | Upregulated in G3 compared with G2 (with Fisher ratio more than 1.3) | Prognostic | G2 (moderately differentiated) HCV-HCC v/s G2 (poorly differentiated) HCV-HCC; associated with invasion or metastsis | P < 0.005 | Tissue | 15710396 |
| 2590 | MPV17, EST, GZMB, ITGA6, EST, CENPC1, EST, SPP1, RTF1, CYB5-M, P4HA2, DNMBP, EST, DNAJB4, PRH1, STK23, TCF2, POSTN, SPP1, WIZ, OSMR, EST, ILIA, CD44, EST, MUC6, MTHFD2, ANXA2, PCSK2, RBP1, EST, ITGA6, APRT, PDUM3, TPM2, RNASE3, OSMR, GRK1, SLC14A, FETUB, ANXA2P1, UGT2B15, EST, KIAA0703, AKAP10, AVPR | RNAs | Human | Genes associated with EHR of HCC | Prognostic | Extrahepatic recurrence (EHR) v/s Early intrahepatic recurrence (IHR) | P< 0.05 | Tissue | 17016605 |
| 2591 | ITGA6, SPP1, DNMBP, CD44, POSTN | RNAs | Human | Upregulated in HCC with EHR than in HCC without EHR. | Prognostic | HCC with EHR (Extrahepatic recurrence) v/s HCC without EHR. | P< 0.05 | Tissue | 17016605 |
| 2592 | ITGA6, SPP1 | RNAs | Human | Upregulated in HCC with EHR than HCC without EHR and non-cancerous liver tissue ( also higher expression in HCC without EHR than non-cancerous liver tissue) | Prognostic | HCC with EHR (Extrahepatic recurrence) v/s HCC without EHR. | P< 0.05 | Tissue | 17016605 |